Condition
Refractory Hematologic Malignancy clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Refractory Hematologic Malignancy clinical trials that are recruiting, at sites in 13 countries (most in United States (3), Spain (2), Belgium (1)). By phase: Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 13Countries
Newest Refractory Hematologic Malignancy clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Long-term follow-up for patients who received genetically modified cell therapy | — | Memphis, Tennessee | Recruiting | Feb 6, 2023 |
| International Leukemia Target Board for children with relapsed hematologic malignancies | — | Ghent and 6 other locations | Recruiting | Mar 8, 2022 |
| Mobile app to help cancer patients with advance care planning | — | Manhasset, New York and 3 other locations | Recruiting | Aug 17, 2020 |
| Evaluating Emavusertib for Relapsed or Refractory Primary Central Nervous System Lymphoma | Phase 1/2 | Phoenix, Arizona and 44 other locations | Recruiting | Nov 1, 2017 |
All recruiting trials (4)
-
Long-term follow-up for patients who received genetically modified cell therapy
This study is tracking the long-term health effects of gene therapy in patients with blood cancers to see how they are doing 15 years after treatment.
-
International Leukemia Target Board for children with relapsed hematologic malignancies
This study is trying to find the best treatment options for children with relapsed blood cancers by looking at their unique disease characteristics and how they respond to different drugs.
-
Mobile app to help cancer patients with advance care planning
This study tests whether a mobile app can help cancer patients talk about and plan their future care wishes with their families and doctors better than standard care alone.
-
Evaluating Emavusertib for Relapsed or Refractory Primary Central Nervous System Lymphoma
This study is testing a new drug called emavusertib, alone and with another medication, to see if it can help adults with tough-to-treat primary central nervous system lymphoma feel better.
Related topics
Quick answers
How many Refractory Hematologic Malignancy clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 13 countries. The most sites are in United States (3 trials), Spain (2 trials), Belgium (1 trial), Denmark (1 trial), Hungary (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.